Skip to content

A study of the effects of fascial release on the visual acuity of adolescents with pseudo and low myopia

Clinical observation of Fascia Manipulation in the treatment of visual display terminal asthenopia

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2200005698
Enrollment
Unknown
Registered
2021-07-05
Start date
2021-07-09
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Video terminal visual fatigue, pseudo-myopia, low-level myopia

Interventions

Sponsors

Guangzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 25 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-25 years, no gender limit; 2. Meet the VDT diagnostic criteria; 3. Those without organic lesions of the eyes and head; 4. Those who have not been treated or have been treated with other drugs for more than 2 weeks; 5. Proficient in the use of smart phones; 6. Those who signed the informed consent; 7. No history of head trauma or surgery.

Exclusion criteria

Exclusion criteria: 1. Subjects with poor compliance; 2. Subjects with serious diseases (such as diabetes, liver and kidney disease and (or) heart disease, thyroid disease, adrenal disease); 3. Those with other eye diseases (such as infectious conjunctivitis, glaucoma); 4. Subjects diagnosed with presbyopia (the dominant eye's controlled width is less than 2.5 diopters (D)); 5. Subjects with uncorrected severe refractive errors in the dominant eye; 6. Subjects who have undergone ophthalmic surgery; 7. Subjects whose dominant eye can achieve the best corrected visual acuity advantage <1.0; 8. Subjects with serious diseases (such as diabetes, liver disease, kidney disease and (or) heart disease, thyroid disease, adrenal disease); 9. Subjects who often take drugs or health food that may have an effect on the eyes or are expected to use related drugs or health food during the study period; 10. Subjects who may cause drug allergy; 11. Those who plan or have participated in other clinical studies during this study within 3 months.

Design outcomes

Primary

MeasureTime frame
Hemodynamics of the anterior ciliary artery;Hemodynamics of the central retinal artery;Eye symptom score for individual and total scores;

Countries

China

Contacts

Public ContactYe Shisi
yyesyi@163.com+86 15360016824

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026